La surexpression de protéines FGFR2b (IHC 2+/3+ membraneux dans ≥10% des cellules tumorales) identifie un...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-FGFR2B-MEMBRANE-GASTRIC |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-07 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-GASTRIC |
| Sources | SRC-ESMO-GASTRIC-2024 SRC-FORTITUDE-101 SRC-NCCN-GASTRIC-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-FGFR2B-IHC |
|---|---|
| Variante | FGFR2b 2+/3+ coloration membraneuse dans ≥10% des cellules tumorales par IHC sélectif IIIb-isoforme (FORTITUDE-101 / seuil d'admissibilité à la lutte) |
| Maladie | DIS-GASTRIC |
| Niveau ESCAT | IIA |
| Combinaisons recommandées | bemarituzumab + mFOLFOX6 (1L FGFR2b-IHC 2+/3+ ≥10% — régime de phase 2 de lutte; confirmation FORTITUDE-101) |
| Contre-indiqué en monothérapie | bemarituzumab monotherapy (no registration data; chemotherapy backbone required per FIGHT / FORTITUDE-101 designs) |
| Résumé des faits | FGFR2b protein overexpression (IHC 2+/3+ membranous in ≥10% of tumor cells) identifies a ~30% subset of HER2-negative metastatic gastric / GEJ adenocarcinoma sensitive to bemarituzumab — anti-FGFR2b chimeric IgG1 monoclonal antibody with afucosylated Fc enhancing ADCC. FIGHT phase 2 (Wainberg et al. Lancet Oncol 2022): bemarituzumab + mFOLFOX6 vs placebo + mFOLFOX6 in FGFR2b-overexpressing 1L gastric — mPFS 9.5 vs 7.4 mo (HR 0.68), mOS 19.2 vs 13.5 mo (HR 0.60); benefit greater at higher FGFR2b cutoffs (≥10% vs all-comer). Phase 3 confirmatory trial FORTITUDE-101 (interim data — full readout pending; source stub flagged). Distinct from FGFR2 gene amplification (covered by BMA-FGFR2-AMP-GASTRIC) — IHC selects on protein expression of the IIIb isoform regardless of underlying gene amp status. Adverse-event profile dominated by ocular toxicity (corneal events ~70% any-grade, ~25% grade ≥3) — mandatory baseline + serial slit-lamp ophthalmologic exams. |
Notes
ESCAT IIA — phase 2 randomized data (FIGHT) supports the cell; confidence will upgrade to IA upon full FORTITUDE-101 publication. CITATION GAP: SRC-FORTITUDE-101 is currently a TODO-stub (legal review pending, title placeholder). Cited as-is per chunk-spec instruction; upgrade is a separate housekeeping task. Distinguishing this BMA from BMA-FGFR2-AMP-GASTRIC (gene amplification → off-label TKI / basket trial activity) — the protein-IHC and gene-amp tests overlap in ~50% of cases but each captures a distinct subset (FIGHT data, Wainberg Lancet Oncol 2022). Hierarchy when multiple biomarkers co-positive: HER2+ (TOGA / KEYNOTE-811) > MSI-H (KEYNOTE-859) > CLDN18.2+ (SPOTLIGHT / GLOW) > FGFR2b+ (FIGHT / FORTITUDE-101). Ocular toxicity is the dose-defining AE — protocol-driven ophthalmology pre-treatment + ongoing slit-lamp surveillance.
Utilisé par
No reverse references found in the YAML corpus.